Ridgeback Biotherapeutics is a Miami-based biotechnology company, primarily known for its involvement in developing a successful COVID-19 medication.
Ridgeback is privately owned by hedge fund manager and physician, Wayne Holman (formerly of S.A.C.
Molnupiravir was initially researched as a treatment for influenza, but may have broad spectrum activity against other viruses.
Ridgeback was mentioned in a whistleblower complaint from Rick Bright, former director of the Biomedical Advanced Research and Development Authority.
Ridgeback has also developed a number of other advanced medications such as monoclonal antibody Ansuvimab against the Ebola virus.